Pharmala Biotech Holdings Inc
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc (MDXXF) - Total Liabilities
Latest total liabilities as of November 2025: $1.03 Million USD
Based on the latest financial reports, Pharmala Biotech Holdings Inc (MDXXF) has total liabilities worth $1.03 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmala Biotech Holdings Inc - Total Liabilities Trend (2021–2025)
This chart illustrates how Pharmala Biotech Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmala Biotech Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Pharmala Biotech Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wow Factor PCL
BK:W
|
Thailand | ฿586.93 Million |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
USA | $451.87K |
|
Daewoo SBI SPAC 1
KQ:215480
|
Korea | ₩8.10 Billion |
|
Aurea SA
PA:AURE
|
France | €127.72 Million |
|
Sparc Technologies Ltd
AU:SPN
|
Australia | AU$1.13 Million |
|
Advancecon Holdings Bhd
KLSE:5281
|
Malaysia | RM385.43 Million |
|
Mendus AB (publ)
ST:IMMU
|
Sweden | Skr43.26 Million |
|
YD More Investments Ltd
TA:MRIN
|
Israel | ILA449.05 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Pharmala Biotech Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmala Biotech Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmala Biotech Holdings Inc (2021–2025)
The table below shows the annual total liabilities of Pharmala Biotech Holdings Inc from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $961.73K | +4.89% |
| 2024-08-31 | $916.88K | -10.90% |
| 2023-08-31 | $1.03 Million | +142.82% |
| 2022-08-31 | $423.78K | +206.03% |
| 2021-08-31 | $138.48K | -- |